Literature DB >> 11391602

Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases.

T J Sebo1, J C Cheville, D L Riehle, C M Lohse, V S Pankratz, R P Myers, M L Blute, H Zincke.   

Abstract

BACKGROUND: DNA ploidy analysis of prostate carcinoma is a generally accepted prognostic marker, particularly when tumors are extraprostatic at the time of surgery. In the past decade, the DNA content of prostate carcinoma frequently has been assessed in needle biopsy specimens based on the assumption that ploidy, in conjunction with serum prostate specific antigen (PSA) and Gleason score, provides valuable pretreatment information.
METHODS: Between 1995 and 1998, the authors identified a consecutive series of 454 prostate carcinomas, verified by needle biopsies and followed by radical retropubic prostatectomies (RRP). Based on the needle biopsies, DNA ploidy and MIB-I immunostaining were measured by digital image analysis (DIA). The authors also quantified the percent of nuclei in four categories from the DNA histograms. The DIA data were combined with the age of the patient at diagnosis, the serum PSA, Gleason score, percent cores and percent surface area positive for carcinoma, and status of perineural invasion in multivariate models using tumor volume and risk of extraprostatic extension (EPE) at RRP as the outcome variables.
RESULTS: Joint predictors of tumor volume at RRP were the percent cores positive for carcinoma (P < 0.0001), serum PSA (P < 0.0001), the percent surface area positive for carcinoma (P < 0.0001), and the percent nuclei classified by DNA quantification to be in the "S-phase" category (P = 0.03). Joint predictors of risk of EPE were the percent cores positive for carcinoma (P = 0.0004), a Gleason score of 7 (P < 0.0001), a Gleason score of 8 or 9 (P < 0.0001), serum PSA (P = 0.006) and perineural invasion (P = 0.02).
CONCLUSIONS: After adjusting for traditional prognostic markers, DNA ploidy interpretation and MIB-I quantitation of prostate carcinoma did not appear to jointly predict either outcome variable in the multivariate models. However, a quantitative measure related to both ploidy and proliferation, the percent of nuclei in the putative "S-phase" category from the DIA histograms, was found to jointly predict for tumor volume. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11391602     DOI: 10.1002/1097-0142(20010601)91:11<2196::aid-cncr1249>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.

Authors:  Minoru Kobayashi; Akinori Nukui; Kazumi Suzuki; Shinsuke Kurokawa; Tatsuo Morita
Journal:  Int J Clin Oncol       Date:  2011-04-23       Impact factor: 3.402

Review 2.  Histopathology reporting of prostate needle biopsies. 2005 update.

Authors:  Rodolfo Montironi; Remigio Vela Navarrete; Antonio Lopez-Beltran; Roberta Mazzucchelli; Gregor Mikuz; Aldo V Bono
Journal:  Virchows Arch       Date:  2006-04-22       Impact factor: 4.064

3.  Various morphometric measurements of cancer extent on needle prostatic biopsies: which is predictive of pathologic stage and biochemical recurrence following radical prostatectomy?

Authors:  Maisa M Q Quintal; Luciana R Meirelles; Leandro L L Freitas; Luis A Magna; Ubirajara Ferreira; Athanase Billis
Journal:  Int Urol Nephrol       Date:  2011-02-22       Impact factor: 2.370

Review 4.  Biomarker research in prostate cancer--towards utility, not futility.

Authors:  Sheng Fei Oon; Stephen R Pennington; John M Fitzpatrick; R William G Watson
Journal:  Nat Rev Urol       Date:  2011-03       Impact factor: 14.432

Review 5.  [Molecular biomarkers and prognostic factors for prostate cancer].

Authors:  A Kretschmer; Y Tolkach; J Ellinger; G Kristiansen
Journal:  Urologe A       Date:  2017-07       Impact factor: 0.639

6.  Prostate cancer at the peripheral end of prostate biopsy specimen predicts increased risk of positive resection margin after radical prostatectomy: results of a prospective multi-institutional study.

Authors:  Anton Ponholzer; Sophina Trubel; Paul Schramek; Florian Wimpissinger; Hans Feichtinger; Christopher Springer; Clemens Wehrberger; Katja Fischereder; Karl Pummer; Thomas Martini; Roman Mayr; Armin Pycha; Stephan Madersbacher
Journal:  World J Urol       Date:  2014-02-08       Impact factor: 4.226

7.  Can we predict real T3 stage prostate cancer in patients with clinical T3 (cT3) disease before radical prostatectomy?

Authors:  Hye Won Lee; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Han Yong Choi
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

Review 8.  Pathologic basis of focal therapy for early-stage prostate cancer.

Authors:  Vladimir Mouraviev; Janice M Mayes; Thomas J Polascik
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

9.  Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases.

Authors:  Grant Chavin; Yuri Sheinin; Paul L Crispen; Stephen A Boorjian; Timothy J Roth; Laureano Rangel; Michael L Blute; Thomas J Sebo; Don J Tindall; Eugene D Kwon; R Jeffrey Karnes
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

10.  Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy.

Authors:  Sumit Isharwal; Michael Craig Miller; Jonathan I Epstein; Leslie A Mangold; Elizabeth Humphreys; Alan W Partin; Robert W Veltri
Journal:  Int J Cancer       Date:  2008-12-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.